tbuckley/cabot-search huggingface dataset:
Assessment of Epidemiology Capacity in State Health Departments — United States, 2017
Authors: Jessica Arrazola, Nancy Binkin, Maria Israel, Aaron Fleischauer, Elizabeth R. Daly, Robert Harrison, Jeffrey Engel
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

In 2017, the Council of State and Territorial Epidemiologists performed its sixth periodic Epidemiology Capacity Assessment, a national assessment that evaluates trends in workforce size, funding, and epidemiology capacity among state health departments. A standardized web-based questionnaire was sent to the state epidemiologist in the 50 states, the District of Columbia (DC), and the U.S. territories and the Federated States of Micronesia inquiring about the number of current and optimal epidemiologist positions; sources of epidemiology activity and personnel funding; and each department's self-perceived capacity to lead activities, provide subject matter expertise, and obtain and manage resources for the four Essential Public Health Services (EPHS)* most closely linked to epidemiology. From 2013 to 2017, the number of state health department epidemiologists† increased 22%, from 2,752 to 3,369, the greatest number of workers since the first full Epidemiology Capacity Assessment enumeration in 2004. The federal government provided most (77%) of the funding for epidemiologic activities and personnel. Substantial to full capacity (50%-100%) was highest for investigating health problems (92% of health departments) and monitoring health status (84%), whereas capacity for evaluating effectiveness (39%) and applied research (29%) was considerably lower. An estimated additional 1,200 epidemiologists are needed to reach full capacity to conduct the four EPHS. Additional resources might be needed to ensure that state health department epidemiologists possess the specialized skills to deliver EPHS, particularly in evaluation and applied epidemiologic research.
CURRENT MEDICAL TERMINOLOGY
Authors: Vera Pyle
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Introduction to Physical Biochemistry
Authors: J. M. Johlin
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The power of shame
Authors: P. Davies
Journal: BMJ (2002)

Innuendo in article is insultingEditor-Yamey and Wilkes offer tabloid journalism to advance their position by saying that they dared to tread on the toes of a powerful pro-screening lobby. 1 They point out that this lobby has major competing interests, since it has a financial stake in offering investigations and treatments for prostate cancer.Even some of the charity groups in this lobby have competing interests, since they receive funding from manufacturers of treatments for prostate cancer or have ties with the American Urological Association.The backlash against their piece, they say, smells like a battle to hold on to power and money.I am a survivor of prostate cancer caught by screening, and I am insulted by the impli-cation that we survivors who object to their distortion of evidence on screening for prostate cancer are part of a dark conspiracy, a "lobby" orchestrated by powerful self serving interests.We survivors want only one thing: that no man be "blind sided" by prostate cancer because of ignorance of the potential and thus no opportunity to exercise the right to decide for himself.Nobody tells us what to say, nor what we want.In September 1994 I was "caught" by screening during the annual prostate cancer awareness week, with prostate specific antigen (PSA) of 14 ng/ml at the age of 57.This prompted the urology consultation that found an irregular prostate gland by digital rectal examination, and the resulting ultrasound guided biopsy found four cores out of seven cancerous.In December 1994 another asymptomatic man, because of my experience with screening, received a diagnosis at age 64, PSA 4 + , but a more aggressive cancer on biopsy (Gleason 4 + 3).He chose not to intervene.In September 1997 his PSA was 10, in December 1997, 90.He was buried in the summer of 1998, his last months in a morphine induced stupor.My intervention, on the other hand, was state of the art for the time, a combination of hormonal ablation, external radiation, and implanted radiation.My PSA on 16 July 2001 was 0.11 ng/ml.My quality of life is compromised only by mild urinary urgency and increased frequency, and a slightly less than average sexual capability for a man of 64.Small inconveniences compared with dying.Pain associated with screening?Discomfort more accurately describes the process itself.Psychological trauma?Compared with dying, minimal.Mortality from prostate cancer declined over 18% from 1993 to 1998.Screening works.But, more importantly, men do not need protective paternalistic doctors interfering with their health decisions by presenting distortions of studies and research as anti-screening fact.
Marine Hygiene and Sanitation. A Manual for Ships' Surgeons and Port Health Officers.
Authors: Gilbert E. Brooke
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group Filmc
Authors: Delphine Rea, Franck E. Nicolini, Michel Tulliez, Philippe Rousselot, Francois Guilhot, Martine Gardembas, Agnès Guerci, Valérie Coiteux, Laurence Legros, Gaelle Guillerm, Jean Michel Pignon, Stephane Giraudier, Gabriel Etienne, Bruno Villemagne, Martine Escoffre, Aude Charbonnier, Francois-Xavier Mahon
Journal: Blood (2014)
Tuberculosis in Infancy and Childhood. Lectures Delivered at the Children's Hospital, Philadelphia, under the Auspices of the Philadelphia Pediatric Society.
Authors: J. Claxton Gittings, Frank Crozer Knowles, Astley P. C. Ashhurst
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Le terrain cancéreux et cancérisable; Physiologie pathologique du cancer. Action biologique des radiations.
Authors: R. Reding
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dose finding and safety analysis of inecalcitol in combination with a docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients
Authors: J. Medioni, G. Deplanque, T. Maurina, J. M. Ferrero, J. M. Rodier, E. Raymond, J. Allyon, S. Kalla, J. F. Dufour-Lamartinie, S. Oudard
Journal: Journal of Clinical Oncology (2009)

5151 Background: Inecalcitol is a novel synthetic vitamin D3 analogue with potent antiproliferative effects in human cancer cell lines and a 100-fold lower hypercalcemic activity than calcitriol in animal models. Methods: Escalating dosages of inecalcitol were combined to chemotherapy in naive HRPC patients (pts). Safety and efficacy were evaluated in groups of 3–6 patients receiving oral inecalcitol daily or every other day on a 21-day cycle in combination with docetaxel (75mg/m2 q3w) and oral prednisone (5mg bid). Biphosphonates were prohibited during the first cycle. Patients received up to six cycles unless unacceptable toxicity or disease progression. Primary endpoint was dose limiting toxicity (DLT) defined as grade 3 hypercalcemia within the first cycle. Calcemia, creatininemia and CBC were assessed weekly; biochemistry, ECG and PSA every 3 weeks. Efficacy endpoint was PSA response defined as ≥30% decline within 3 months. Results: Five dose levels: 40, 80, 160, 300, 600 μg have been evaluated in 34 pts; 9 pts are still being treated at 600 μg; 25 pts have completed 6 cycles (13 bone metastases; 3 extrasqueletic metastasis, 8 bone and extrasqueletic metastases; 1 PSA-only disease). Median age was 72 years (range, 53–87), median Gleason score (Gs) 7 (36% Gs 10–8, 64% Gs 7–6) and median PSA 41.5 ng/mL (range, 0.9–962.4). No increased calcemia was reported. Most adverse events (AE) were G1–2, asthenia (19pts), constipation (14pts), diarrhea (13pts). G3–4 AEs were neutropenia (11pts) lymphopenia (9pts), asthenia (3pts), arrhythmia (2 pts), general health deterioration (2pts) and diarrhea (1pt). None of these AEs was considered related to inecalcitol. Of the 23 evaluable pts for PSA response, 20 (87%) had ≥30% PSA decline. Conclusions: Results from this ongoing study show the safe profile of inecalcitol when given daily in in HRPC pts. PSA responses with this combination are encouraging. As DLT was not reached, a higher dose of inecalcitol (1000 μg/day) will be further tested. [Table: see text]
Annual Review Hospital Visits for Patients with Cystic Fibrosis
Authors: Jennifer M Long, Janice Fauset-Jones, Moira J Dixon, Debra Worthington-Riley, Vibha Sharma, Leena Patel, T J David
Journal: Journal of the Royal Society of Medicine (2001)

Cystic fibrosis (CF) is a lifelong multisystem disease. All patients attend hospital on a regular basis for review and adjustment of treatment. They are treated in the clinic by a multidisciplinary team, all with a special interest and expertise in CF. The composition of the team varies somewhat, but usually comprises a doctor, a nurse, a physiotherapist and a dietition. Other departments variously involved include the ward nursing staff, radiology/imaging, social work, psychology, psychiatry, microbiology, gastroenterology/nutrition, surgery, pharmacy and the hospital contracts department. Little current treatment in CF is based on evidence from randomized controlled clinical trials, and many treatment regimens have been introduced into practice with no objective evaluation. Thus it is that without any controlled studies of benefit or cost, it has become the received wisdom and part of standard guidelines in the UK that all patients with CF should, in addition to regular 3-monthly hospital visits, attend for an in-depth review once a year1. The principle of this is to enable a much more detailed proactive appraisal than is possible during the routine outpatient clinic. In most centres, including ours, this annual review visit replaces a routine 3-monthly appointment. The immediate effect of annual review visits is to generate considerably increased activity by both patients (attending hospital, filling in diet or activity diaries) and staff, as well as consuming additional resources. The assumption is that all this additional activity is beneficial, but this has never been objectively demonstrated. Indeed, an obvious question, which has never been addressed, is why an annual review should be needed for patients who are already receiving a 3-monthly one. Annual reviews are so well established as part of routine practice that it would now be impossible to perform a randomized controlled trial. In order to try and evaluate annual reviews, we decided to test the hypothesis that annual review visits generate a larger number of interventions than are generated during routine outpatient clinic visits, using the number of medical, dietetic and physiotherapy interventions per attendance as the primary outcome variables.
Proceedings of the Third International Congress of the International Society of Hematology, Cambridge, England, August 21-25, 1950
Authors: Carl V. Moore
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A multicenter review of gemcitabine, docetaxel, and capecitabine (GTX) in patients with advanced pancreatic adenocarcinoma.
Authors: A. De Jesus-Acosta, G. R. Oliver, E. Flores, L. S. Wilfong, D. Laheru, D. T. Le, L. Zheng, R. C. Donehower, D. Cosgrove, L. A. Diaz
Journal: Journal of Clinical Oncology (2010)

e14580 Background: Combination chemotherapy provides modest benefit in patients with advanced pancreatic adenocarcinoma over single agent gemcitabine. Recent studies have suggested that new regimens that included taxanes may be active in this disease. One of the more promising regimens combines gemcitabine with docetaxel and capecitabine (GTX) reporting a median survival of greater than 1 year. We were interested in confirming these observations in our patient population. Methods: We performed a multicenter review of all patients with pathologically confirmed locally advanced or metastatic pancreatic adenocarcinoma who received treatment with GTX. Results: Clinical outcomes on 70 patients (36 locally advanced and 34 metastatic pancreatic adenocarcinoma) were collected. Patients had a mean age of 60.6 (range 39-81) and ECOG performance 0-1. Forty-seven percent of patients were deceased at time of this review. GTX was delivered every 21 days (gemcitabine 750 mg/m2 fixed dose rate D4 and D11, docetaxel 30 mg/m2 D4 and D11, capecitabine 1,000 mg bid D1-14) and used as the first-line therapy in 66% of cases. Median overall survival from the time of GTX initiation was 12.4 months, which improved to 14.3 months when used as a first-line regimen; one-year survival was 53% and 61% respectively. In patients with metastatic disease the median overall survival was 12.4 months with a one-year survival of 55%. More than half of patients with metastatic disease had at least a 50% drop in CA19-9. Response rate by RECIST criteria at one institution showed a 24.3% objective response rate (CR + PR) with one complete response, and the majority (70%) of patients exhibiting stable disease. Grade 3-4 hematological toxicities were neutropenia 40%, thrombocytopenia 12.5% and anemia 10%. Hospital admissions were required in 33% (23/70) of the patients while receiving GTX. There were no deaths attributed to toxicity from this regimen. Conclusions: GTX has a promising survival benefit of greater than 1 year in patients with advanced pancreatic adenocarcinoma when compared to studies using single agent gemcitabine or other combination chemotherapies. Randomized controlled studies in pancreatic cancer with GTX are warranted. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Concordia, Roche Concordia Bristol-Myers Squibb, Concordia, Genentech, Lilly
A Plea for Cold Biopsy, Fulguration and Immediate Bladder Instillation with Epirubicin in Small Superficial Bladder Tumors
Authors: Willem Oosterlinck, Karl-Heinz Kurth, Fritz Schröder, Richard Sylvester, Bernadette Hammond, None and Members of the EORTC GU Group
Journal: European Urology (1993)
Influence of Vegetation Size on the Clinical Presentation and Outcome of Lead-Associated Endocarditis
Authors: Arnold J. Greenspon, Katherine Y. Le, Jordan M. Prutkin, M. Rizwan Sohail, Holenarasipur R. Vikram, Larry M. Baddour, Stephan B. Danik, James Peacock, Carlos Falces, Jose M. Miro, Christoph Naber, Roger G. Carrillo, Chi-Hong Tseng, Daniel Z. Uslan
Journal: JACC. Cardiovascular imaging (2014)
Obstetrics in General Practice
Authors: J. P. Greenhill
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
UK survey shows public confusion about human genetic research
Authors: Susan Mayor
Journal: BMJ (2001)

A major survey has shown that most members of the UK general public are in favour of genetic research for medical purposes but three quarters of those taking part believed that they had too little information on controls on biological developments.

The MORI survey asked 1038 members of the “people's panel”—a randomly recruited panel of the general public, aged 16 and over—how they thought human genetic research should be used and regulated. Nine in 10 people taking part in the survey considered that genetic developments could and should be used to diagnose and achieve cures for diseases.

More than two thirds …
Social Work a Family Builder: A Text-Book for Nurses, Dietitians, Home Demonstration Agents, Home Economists, and Special Teachers.
Authors: Harriet Townsend
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal